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ABSTRACT 
Objective: Deferasirox is a once daily, oral iron chelator approved for treatment of transfusional iron overload in adult and paediatric patients. In 
case of iron overdose or poisoning, immediate attention deferasirox is required in the systemic circulation to counter act the iron. Hence we feel 
that formulation of Oro-dispersible tablets of deferasirox is an ideal approach.  
Methods: FTIR showed that there is no interaction between drug and excipients. Mouth dissolving tablets of Deferasirox were prepared using 
crospovidone, croscarmellose and sodium starch glycolate as superdisintegrants by direct compression method. Dissolution of prepared Oro-
dispersible tablets of Deferasirox was performed using USP type II apparatus in 6.8 pH phosphate buffer at 50 rpm with temperature being 
maintained at 37±0.5o
Results: The tablets prepared were evaluated for various parameters like weight variation, hardness, friability, in-vitro dispersion time, drug 
polymer interaction, drug content, water absorption ratio and wetting time and in-vitro release and were found to be within the limits.  
C. Samples were withdrawn at 10, 15, 20, 30 and 45min time points and were analysed using UV- visible 
spectrophotometer at 245 nm. 
Conclusion: Formulation with crospovidone containing superdisintegrants has shown better in-vitro dissolution profile compared with 
other formulations. In conclusion, development of fast dissolving tablets using superdisintegrants gives rapid drug delivery and rapid onset 
of action. 
Keywords: Oro-dispersible tablets, Superdisintegrants, Deferasirox. 
 
INTRODUCTION 
The oral route of administration still continue to be the most 
preferred route due to its manifold advantages including ease of 
ingestion, pain avoidance, suppleness and most importantly patient 
compliance. Most popular dosage form being tablets and capsules, 
even few of the drawbacks of these dosage forms like swallowing 
and some drugs resist comparison in dense compacts, owing to their 
amorphous nature or flocculants, low density characteristics. Drugs 
with poor wetting, slow dissolution properties, intermediate to large 
dosage, and optimum absorption in the gastrointestinal tract or any 
combination of these features may be difficult or impossible to 
formulate and manufacture as a tablet that will still provide 
adequate or full drug bioavailability. Bitter tasting drugs, drugs with 
an objectionable odour, or drugs that are sensitive to oxygen or 
atmospheric moisture may require encapsulation or entrapment 
prior to compression. The target population of these dosage forms 
are paediatric, geriatric, bedridden, developmentally disabled and 
the patients with tenacious nausea or who have little access to 
water. Even many patients find it difficult to swallow tablets and 
hard gelatin capsules and thus do not comply with prescription, 
which results in high incidence of non-compliance and ineffective 
therapy.  
Recent advances in novel drug delivery systems (NDDS) aim to 
enhance safety and efficacy of drug molecule by formulation and to 
achieve better patient compliance. One such approach is ‘mouth 
dissolving tablets’ which disintegrate or dissolve in saliva and are 
swallowed without water as tablet disintegrate in mouth, this could 
enhance the clinical effect of drug through pre-gastric absorption 
from the mouth, pharynx, oesophagus, this leads to an increase in 
the bioavailability by avoiding first pass liver metabolism [1]. 
These tablets display a fast and spontaneous de-aggregation in the 
mouth, soon after the contact with saliva, though they can be 
handled or extracted from the package without alteration. The active 
agent can thus rapidly dissolve in the saliva and be absorbed 
through whatever membrane it encounters, during deglutition, 
unless it is protected from pre-gastric absorption. To fulfill these 
requirements, tablets must be highly porous, incorporating 
hydrophilic excipients, able to rapidly absorb water for a rapid 
deaggregation of the matrix. Different technological techniques, such 
as freeze drying or molding or direct compression are currently 
employed to prepare the formulations of this type present on the 
pharmaceutical market [1,2]. 
Honda and Nakano reported that a half of the patients surveyed 
experienced difficulty in taking medication and felt that a tablet was 
a better and easier formulation compared to other formulations such 
as capsules or powder. They also reported that the degree of ease 
when taking a tablet depended on its size. They reported that the 
size of tablet that was easiest to swallow was 7–8 mm, but the size 
easiest to handle was one larger than 8 mm [3]. Tanmoy ghosh et. al., 
exploration on new generation oro-dispersible tablets and its future 
prospective concluded that future challenges includes reducing costs 
by finding ways to manufacture with conventional equipment, using 
versatile packing and improving mechanical strength and taste 
masking capabilities [4]. Kulkarni maushumi S et. al., formulated and 
evaluated oro-dispersible tablet of ornidazole, masked microspheres 
were prepared and then formulated into oro-dispersible tablets 
using the technique of superdisintegrating addition [5] Shid S. L et. 
al., formulated effect of superdisintegrants in rapidly disintegrating 
flurbiprofen sodium oro-dispersible tablets via direct compression 
and camphor sublimation. Thus it was concluded that the stable oro-
dispersible tablets of flubiprofen can be developed for the rapid 
release of flurbiprofen [6]Khalid K. Abed et. al., formulated Oro-
dispersible tablets of diazepam. Diazepam tablets were prepared 
using different types of superdisintegrants and subliming agents at 
different concentrations and two methods of preparation by wet 
granulation and direct compression methods [7] P. V. Swamy et. al., 
formulated design and evaluation of cost effective oro-dispersible 
tablets of diethylcarbamazine citrate by effervescent method. In 
effervescent method mixture of sodium bicarbonate and tartaric 
acid along with treated agar were used as disintegrants [8] 
Abdelbary G et. al., formulated and determined the in-vitro 
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disintegration profile of rapidly disintegrating tablets and 
correlation with oral disintegration. Correlation of in-vitro 
disintegration times is compared with oral times [9].Takao 
Mizumoto et. al., formulated design of a novel fast-disintegrating 
tablet having sufficient hardness and manufactured by commonly 
used equipment.  
The process included using of saccharides with high and low 
compressibility such that to achieve adequate hardness and quick 
disintegration [10] Indhumathi D. formulated Oro-dissolving tablets 
by superdisintegrants addition method by using Fluoxetine. The 
tablets were prepared by wet granulation method and evaluated for 
hardness, thickness, friability, weight variation uniformity of 
content, disintegration time and dissolution studies. In-vitro 
dissolution studies show the release in the following order of 
superdisintegrants: crospovidone > pregelatinized starch > 
croscarmellose > sodium starch glycolate [11]. 
MATERIALS AND METHODS  
Preparation of standard graph of Deferasirox in pH 6.8 
phosphate buffer 
Accurately weighed amount (100 mg) of the drug was dissolved in 
5ml of organic solvent like Dimethyl sulfoxide(DMSO), Dimethyl 
formamide(DMFO) and then dissolved in pH 6.8 phosphate buffer in 
100 ml volumetric flask and the volume was made up to 100ml. 
From this stock solution 10ml is withdrawn in to volumetric flask, 
made the volume up to 100ml with pH 6.8 buffer.  
From this II stock solution (100µg/ml), 20ml is withdrawn and 
made the volume up to 100ml with distilled water.  From this III 
stock solution different concentration of 2, 4, 6, 8, 10µg/ml solutions 
were prepared and the corresponding absorbance was measured at 
245 nm in a UV/Visible spectrophotometer.  
Preparation of Deferasirox Oro-dispersible tablets by Direct 
compression method 
For preparation of deferasirox by direct compression method, the 
formulation includes different list of excipients which are as follows. 
Drug - Deferasirox 
Superdisintegrants- Crospovidone, Croscaramellose, Sodium starch 
glycolate. 
Diluents - Lactose, Mannitol, MCC. 
Lubricant - Talc 
Glidant- Magnesium stearate 
Sweetening agents - Sucrose 
Flavouring agent- Peppermint oil 
The drug, diluent, superdisintegrant, sweeteners, are passed 
through the sieve no-40#. All the ingredients are mixed well in the 
motor.  
Then mixed with a lubricant for 3 min in a motor and then mixer 
was compressed by using 10mm flat punches on sixteen station 
rotary tablet compression machine (Table 1, 2, 3, 4). 
RESULTS AND DISCUSSION 
Preparation of standard graph of Deferasirox 
Deferasirox has the maximum absorbance at 245 nm. Standard 
graph of Deferasirox in pH 6.8 buffer was plotted by taking 
concentrations ranging from 2 to 10 µg/ml and a good correlation 
was obtained with R2
 
 value of 0.9991. 
Table 1: Composition of mouth dissolving tablets of deferasirox (F1-F9) using spray dried lactose as diluent 
Formula F1 F2 F3 F4 F5 F6 F7 F8 F9 
Deferasirox(mg) 150 150 150 150 150 150 150 150 150 
Crospovidone 2% 4% 6% - - - - - - 
Croscarmellose - - - 2% 4% 6% - - - 
SSG - - - - - - 2% 4% 6% 
Peppermint oil 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 
Colouring agent 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 
Sucrose 2% 2% 2% 2% 2% 2% 2% 2% 2% 
Talc 1% 1% 1% 1% 1% 1% 1% 1% 1% 
Magnesium stearate 1% 1% 1% 1% 1% 1% 1% 1% 1% 
Spray dried lactose Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
 
Table 2: Composition of mouth dissolving tablet of deferasirox (F10-F18) by using mannitol as diluent 
Formula F10 F11 F12 F13 F14 F15 F16 F17 F18 
Deferasirox 150 150 150 150 150 150 150 150 150 
Crospovidone 2% 4% 6% - - - - - - 
Croscarmellose - - - 2% 4% 6% - - - 
SSG - - - - - - 2% 4% 6% 
Peppermint oil 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 
Colouring agent 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 
Sucrose 2% 2% 2% 2% 2% 2% 2% 2% 2% 
Talc 1% 1% 1% 1% 1% 1% 1% 1% 1% 
Magnesium stearate 1% 1% 1% 1% 1% 1% 1% 1% 1% 
 Mannitol Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
 
Table 3: Composition of mouth dissolving tablets of deferasirox(F19-F27) by using MCC as diluent. 
Formula F19 F20 F21 F22 F23 F24 F25 F26 F27 
Deferasirox 150 150 150 150 150 150 150 150 150 
Cross povidone 2% 4% 6% - - - - - - 
croscarmellose - - - 2% 4% 6% - - - 
SSG - - - - - - 2% 4% 6% 
Peppermint oil 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 
Colouring agent 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 
Sucrose 2% 2% 2% 2% 2% 2% 2% 2% 2% 
Talc 1% 1% 1% 1% 1% 1% 1% 1% 1% 
Magnesium stearate 1% 1% 1% 1% 1% 1% 1% 1% 1% 
 MCC Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
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Table 4: Composition of mouth dissolving tablets of deferasirox (f28-f30) by using combination of superdisintegrants and mannitol as 
diluents 
Formula F28 F29 F30 
Deferasirox(mg) 150 150 150 
Crospovidone 5% - 5% 
Croscarmellose 5% 5% - 
SSG - 5% 5% 
Peppermint oil 0.05% 0.05% 0.05% 
Colouring agent 0.05% 0.05% 0.05% 
Sucrose 2% 2% 2% 
Talc 1% 1% 1% 
Magnesium stearate 1% 1% 1% 
Mannitol Q.S Q.S Q.S 
 









R 0.9991 2 
 
Evaluation of blend 
Table 6: Evaluation of mixed blend of drug and excipients 
Formula Angle of repose(θ) Bulk density (gm/cm3 Tapped density (gm/cm) 3 Compressibility index (I) ) Hausner’s ratio 
F1 28.3±1.7 0.42±0.16 0.66±0.24 39.2 1.5 
F2 25.6±1.9 0.38±0.21 0.52±0.16 44.5 0.9 
F3 29.4±1.1 0.43±0.13 0.71±0.18 40.2 1.19 
F4 26.3±1.3 0.36±0.15 0.62±0.26 36.4 1.2 
F5 25.3±1.8 0.41±0.13 0.59±0.24 43.1 0.8 
F6 29.4±1.1 0.42±0.12 0.64±0.17 33.3 0.98 
F7 30.0±1.2 0.36±0.17 0.59±0.19 35.4 0.7 
F8 26.8±1.5 0.4±0.16 0.62±0.14 42.3 1.15 
F9 29.3±1.7 0.39±0.23 0.71±0.17 38.1 0.92 
F10 30.0±1.3 0.4±0.17 0.58±0.23 40.6 0.97 
F11 30.0±1.6 0.37±0.3 0.6±0.16 36.5 0.9 
F12 29.7±1.2 0.42±0.15 0.58±0.29 37.2 0.8 
F13 27.5±1.2 0.36±0.12 0.59±0.23 40.6 0.91 
F14 28.4±1.1 0.42±0.15 0.61±0.16 38.7 1.2 
F15 30.2±1.8 0.4±0.14 0.62±0.25 35.4 0.79 
F16 30.4±1.4 0.51±0.25 0.71±0.22 39.7 0.83 
F17 29.2±1.6 0.39±0.17 0.57±0.13 41.3 0.94 
F18 30.0±1.4 0.44±0.15 0.7±0.17 34.9 1.5 
F19 28.7±1.4 0.42±0.21 0.62±0.17 40.3 0.9 
F20 28.5±1.3 0.39±0.11 0.58±0.12 39.4 0.87 
F21 28.4±1.3 0.42±0.13 0.61±0.16 38.7 1.2 
F22 30.2±1.3 0.4±0.26 0.62±0.13 35.4 0.79 
F23 30.4±1.5 0.51±0.19 0.71±0.19 39.7 0.83 
F24 30.0±1.2 0.36±0.16 0.59±0.28 35.4 0.7 
F25 26.8±1.7 0.4±0.23 0.62±0.12 42.3 1.15 
F26 29.3±1.8 0.39±0.14 0.71±0.22 38.1 0.92 
F27 29.2±1.5 0.39±0.18 0.57±0.27 41.3 0.94 
F28 29.7±1.5 0.42±0.11 0.58±0.12 37.2 0.8 
F29 27.5±1.1 0.36±0.16 0.59±0.23 40.6 0.91 
F30 28.5±1.6 0.39±0.13 0.58±0.25 39.4 0.87 
Blend was evaluated for bulk density, tapped density, compressibility index, Hausner ratio, angle of repose (Table 6). All the formulations show 
angle of repose below 300
 
 that mean they show free flowing property. All the formulation has Hausner ratios between the 0.7 to1.5. It indicates all 
the formulations show better flow property.  
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F1 353±1.5 4.62±0.99 3.11±0.03 0.45±0.12 96±5 88.91±0.96 96.4±0.7 
F2 351± 1.6 4.55±0.16 3.19±0.22 0.35±0.14 92±5 90.48±0.52 97.3±0.5 
F3 351±0.9 4.54±0.35 3.46±0.51 0.37±0.08 94±4 92.58±0.45 94.1±0.6 
F4 349±1.8 4.47±0.24 3.27±0.03 0.29±0.19 107±5 91.98±048 98.5±0.2 
F5 348±1.8 4.51±0.29 3.39±0.49 0.57±0.13 99±4 93.32±0.51 97.4±0.4 
F6 350±2.2 4.57±0.33 3.43±0.51 0.58±0.11 87±4 95.25±0.67 98.3±0.7 
F7 349±1.3 4.48±0.31 3.32±0.59 0.33±0.21 88±3 89.62±0.70 94.8±0.8 
F8 351±2.6 4.55±0.22 3.37±0.47 0.56±0.23 107±6 91.48±0.56 99.8±0.4 
F9 350±2.2 4.57±0.37 3.44±.29 0.38±0.16 103±4 94.58±66 98.7±0.3 
F10 351±2.2 4.48±0.33 3.47±0.26 0.39±0.17 126±5 98.31±0.66 95.3±0.8 
F11 352± 2.6 4.58±0.29 3.49±0.43 0.36±0.14 107±6 89.48±0.32 98.6±0.4 
 F12 351±1.3 4.73±0.31 3.52±0.57 0.47±0.27 102±6 95.58±0.75 97.1±0.7 
F13 351±2.2 4.54±0.22 3.43±0.52 0.49±0.19 94±5 97.98±0.48 99.5±0.2 
F14 353±1.8 4.61±0.37 3.49±0.47 0.44±0.22 103±4 93.32±0.71 97.4±0.5 
F15 350±1.8 4.47±0.31 3.50±0.43 0.48±0.17 101±4 96.25±0.37 98.3±0.7 
F16 351±0.9 4.39±1.12 3.46±0.52 0.51±0.21 96±3 95.62±0.30 97.8±0.8 
F17 349±1.3 4.47±1.17 3.57±0.27 0.50±0.19 92±5 91.48±0.96 98.8±0.4 
F18 350±1.5 4.54±0.24 3.52±0.22 0.48±0.27 104±4 97.58±0.86 97.7±0.4 
F19 351±1.8 4.56±1.99 3.50±0.23 0.47±0.21 93±6 89.91±0.96 95.4±0.7 
F20 349± 1.6 4.61±0.26 3.51±0.12 0.51±0.12 108±3 94.48±0.52 98.3±0.5 
F21 350±0.9 4.58±0135 3.46±0.41 0.53±0.09 94±2 96.58±0.45 97.1±1.6 
F22 352±1.9 4.63±0.34 3.46±0.33 0.57±0.27 107±5 96.98±048 98.5±0.26 
F23 351±1.8 4.64±0.21 3.47±0.49 0.54±0.13 103±5 88.32±0.51 94.4±0.4 
F24 350±2.6 4.56±0.33 3.45±0.41 0.51±0.17 99±4 95.25±0.67 96.3±0.4 
F25 349±1.3 4.47±0.38 3.32±0.39 0.43±0.31 101±4 98.62±0.70 97.8±0.5 
F26 351±2.7 4.52±0.26 3.57±0.27 0.56±0.23 103±5 96.48±0.56 96.8±0.3 
F27 352±2.2 4.57±0.37 3.44±.29 0.48±0.36 104±4 97.58±66 95.7±0.5 
F28 349± 1.6 4.61±0.26 3.51±0.12 0.51±0.12 98±3 94.48±0.52 98.3±0.5 
F29 350±1.5 4.54±0.24 3.52±0.22 0.48±0.27 104±4 97.58±0.86 97.7±0.4 
F30 353±1.8 4.61±0.37 3.49±0.47 0.44±0.22 103±4 93.32±0.71 97.4±0.5 
 
Evaluation of tablets 
Weight variation:  
The total weight of each formulation was not maintained constant 
however; the weight variation of the tablets was within the 
permissible limits of 5%, as specified. (Table 7). 
 
Fig. 1: Standard graph of deferasirox in pH 6.8 buffer 
 
 
Fig. 2: Comparison of dissolution profile for F1, F2, F3 batches 
In-vitro dissolution study of formulations F1, F2 and F3 batches 
showed drug release of 87%, 93%, 91% within 30 min. F2 batch 
shown good dissolution profile (Figure 2). F2 batch contain 4% of 
crospovidone as superdisintegrant and Lactose as diluent. 
 
Fig. 3: Comparison of dissolution profile for F4, F5, F6 batches 
 
In-vitro dissolution study of formulations F4, F5 and F6 batches 
showed drug release of 82%, 84% and 90% within 30 min. Among 
these formulations F6 batch shown good dissolution profile (Figure 
3). F6 batch contain 6% of Croscarmellose as superdisintegrant and 
Lactose as diluent. 
 
 
Fig. 4: Comparison of dissolution profile for F7, F8, F9 batches 
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In-vitro dissolution study of formulations F7, F8 and F9 batches 
showed drug release of 84%, 87% and 91% within 30 min. Among 
these formulations F9 batch shown good dissolution property 
(Figure 4). F9 batch contain 6% of sodium starch glycolate as 
superdisintegrant and lactose as diluent.  
 
 
Fig. 5: Comparison of dissolution profile for F10, F11, F12 
batches 
 
In-vitro dissolution study of formulations F10, F11 and F12 batches 
showed drug release of 82%, 85% and 90% within 30 min. Among these 
formulations F12 batch shown good dissolution profile (Figure 5). F12 
batch contain 6% of crospovidone as superdisintegrant and 
mannitol as diluent.  
 
 
Fig. 6: Comparison of dissolution profile for F13, F14, F15 
batches 
 
In-vitro dissolution study of formulations F13, F14 and F15 batches 
showed drug release of 80%, 83% and 86% within 30 min. Among 
these formulations F15 batch shown good dissolution property 
(Figure 6). F15 batch contain 6% of croscarmellose as 
superdisintegrant and mannitol as diluent. 
 
 
Fig. 7: Comparison of dissolution profile for F16, F17, F18 
batches 
 
In-vitro dissolution study of formulations F16, F17 and F18 batches 
showed drug release of 81%, 85% and 88% within 30 min. Among these 
formulations F18 batch shown good dissolution profile (Figure 7). F18 
batch contain 6% of sodium starch glycolate as superdisintegrant 
and mannitol as diluent. 
 
 
Fig. 8: Comparison of dissolution profile for F19, F20, F21 
batches 
 
In-vitro dissolution study of formulations F19, F20 and F21 batches 
showed drug release of 81%, 84% and 88% within 30 min. Among 
these formulations F21 batch shown good dissolution property 
(Figure 8). F21 batch contain 6% of crospovidone as 
superdisintegrant and Micro crystalline cellulose as diluent. 
 
 
Fig. 9: Comparison of dissolution profile for F22, F23, F24 
batches 
 
In-vitro dissolution study of formulations F22, F23 and F24 batches 
showed drug release of 80%, 82% and 84% within 30 min. Among 
these formulations F24 batch showed good dissolution property 
(Figure 9). F24 batch contain 6% of croscarmellose as 
superdisintegrant and Micro crystalline cellulose as diluent.  
 
 
Fig. 10: Comparison of dissolution profile for F25, F26, F27 
batches 
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In-vitro dissolution study of formulations F25, F26 and F27 batches 
showed drug release of 80%, 82% and 85% within 30 min. Among 
these formulations F27 batch showed good dissolution property 
(Figure 10). F27 batch contain 6% of sodium starch glycolate as 
superdisintegrant and Micro crystalline cellulose as diluent.  
 
 
Fig. 11: Comparison of dissolution profile for F28, F29, F30 
batches 
 
In-vitro dissolution study of formulations F28, F29 and F30 batches 
showed drug release of 83%, 85% and 81% within 30 min. Among 
these formulations F29 batch showed good dissolution property 
(Figure 11). F29 batch contain 4% of crospovidone and 4% of 
sodium starch glycolate as superdisintegrants in combination and 
mannitol as diluent.  
 
 
Fig. 12: Comparison of dissolution profile for F2, F6, F9 batches 
containing lactose as diluent. 
 
In-vitro dissolution study of formulation F2 batch release the drug 
93% within 30 min and other batches showed (Figure 12) less 
percentage of drug release than F2 batch. F2, F6 and F7 batches 




Fig. 13: Comparison of dissolution profile for F12, F15, F18 
batches containing mannitol as diluent. 
In-vitro dissolution study of formulation F12 batch release the drug 
90% within 30 min and other batches showed (Figure 13) less 
percentage of drug release than F12 batch. F12, F15 and F18 batches 




Fig. 14: Comparison of dissolution profile for F21, F24, F27 
batches containing MCC as diluent. 
 
In-vitro dissolution studies of formulation F21 batch release the drug 
88% within 30 min and other batches showed (Figure 14) less 
percentage of drug release than F21 batch. F21, F24 and F27 batches 




Fig. 15: Comparison of dissolution of F2, F12, F21 batches. 
 
In-vitro dissolution study of formulation F2 batch containing 
superdisintegrant crospovidone release the drug 93% within 30 min 
and other batches showed (Figure 15) less percentage of drug 
release than F2 batch. 
It clearly shows due to the superdisintegrant – crospovidone (4%) 
and it seems to be the best. The reason is its highly porous structure 
and water wicking mechanism into porous network of tablet and 
hence increases in concentration of crospovidone accounts for rapid 
drug release. 
Among the formulations (F1-F30), F2 batch has shown good release 
of drug within 30 min. F2 batch contain crospovidone as 
superdisintegrant and lactose as diluent. Compared with other 
superdisintegrants, crospovidone has good disintegration property 
which enables good dissolution of the formulation, whereas 
croscarmellose and SSG have delayed disintegration, due to their 
tendency to gel more than crospovidone. On the other side lactose 
and mannitol have good solubility than microcrystalline cellulose. 
Compared to mannitol, lactose has slight increase in solubility, so it 
enables easy and fast release of the drug. Whereas microcrystalline 
cellulose is insoluble in water, which forms compact tablet, hence 
slow release of drug. 
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So, it is assumed that 4% crospovidone with lactose as diluent is 
optimized in which it shown a drug release of 93% compared with 
other batches. 
Fourier transform infrared spectroscopy 
The IR spectra of pure deferasirox drug showed the characteristic 
absorption bands are as follows: COO- at 1680 cm-1, aliphatic 
triazolidine stretching at 3085 cm-1, O-H stretching of aromatic ring 
at 1351 cm-1, carboxyl keto group showed absorption band at 1607 
cm-1, and strong bending mode at 900-650 cm-1(Spectra 1). No 
drug-polymer interaction was observed in the FTIR spectra of the 
powder mixture of optimized formulation (Spectra 2) since the 
absorption peaks of the drug still could be detected in the mixture. 
 Fig. 16: FTIR spectrum of Deferasirox 
 
 
Fig. 17: FTIR spectrum of Optimized formulation 
 
 
Fig. 18: FTIR spectrum of Placebo 
CONCLUSION 
Deferasirox fast disintegrating tablets were successfully 
formulated by employing direct compression method and found to 
show the significant level of drug release. From the in-vitro 
dissolution studies the formulation F2 were found to be better 
formulations and the dissolution efficiency was increased. FTIR 
study showed that there is no interaction between the drug and 
excipients. In conclusion, development of fast disintegrating 
tablets using superdisintegrants is able to give rapid drug delivery 
and there by rapid onset of action. 
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ABBREVIATIONS 
CCS: Croscarmellose sodium, SSG: Sodium Starch Glycolate, CP: 
Crospovidone, H: Hour, mg: Milligram, min: Minute, mL: Milliliter, N: 
Normality, rpm: Revolution per minute, Sec: Second, USP: United 
States of Pharmacopoeia, UV: Ultraviolet, Wt.: Weight, w/w: Weight 
by weight, mcg: Microgram, %: Percentage, Meq: Milli equilvalent, 
Lit:Litre, FDT: Fast disintegrating tablets, MD: mouth dissolving 
tablet, WHO: World health organization, FT-IR: Fourier Transform 
Infra-Red,  
REFERENCES 
1. Hisakadzu.S. and Bi.Y. Preparation, evaluation and optimization 
of rapidly disintegrating tablets. Powders 
Technol.2002;122:188-98. 
2. Schiermeier, and Schmidt P.C. Fast dispersible ibuprofen 
tablets. Eur. J. Pharm.Sci.2002;15:295-305. 
3. Honda, Y. and Nakano, M., 1998. Evaluation of preference for 
swallowing orally disintegrating famotidine tablet in 
outpatients. Jpn. J.Hosp. Pharm.1998;24:533-40. 
4. Ghosh T, Ghosh A and Prasad D. A review on new generation oro-
dispersible tablets and its future prospective. International Journal 
of Pharmacy and Pharmaceutical Sciences.2011;3(1):1-7. 
5. Kulkarni MS. Formulation and Evaluation of Oro-dispersible 
tablet of Ornidazole. IJPSR.2010;1 (2):39-47. 
6. Shid SL, Hiremath SP, Borkar SN, Sawant VA. Effect of 
superdisintegrants in rapidly disintegrating Flurbiprofen 
sodium Oro-dispersible tablets via direct compression. JGPT. 
2010;2(1):107-17. 
7. Khalid K.Abed, Ahmed A.Hussein, Mowafaq M.Ghareeb. 
Formulation and Optimization of Oro-dispersible tablets of 
Diazepam. AAPS PharmSciTech. 2010;11(1)
8. Swamy PV, Gada SN, Shirsand SB, Kinagi MB and Shilpa H. 
Design and evaluation of cost effective oro-dispersible tablets. 
IJPSR. 2010;1 (6):258-64. 
:356–61. 
9. Abdelbary G, Eouani C, Prinderre P, Joachim J, Reynier JP. 
Determination of the in-vitro disintegration profile of rapidly 
disintegrating tablets and correlation with oral disintegration. 
Int J Pharm. 2005;292(1-2):29-41. 
10. Mizumoto T, Masuda Y, Yamamoto T. Formulation design of a 
novel fast-disintegrating tablet. Int J Pharm. 2005;306:83-90. 
11. Indhumathi D, Rathnam G. Design and optimization of 
orodissolving tablet of antidepressant drug by 
superdisintegrant addition method. Int. J. of Pharm. Sci. Review 
and Res. 2010;2(2):1-9 
                               
 
